For instance, the enhancer of zeste 2 (EZH2) inhibitor EPZ6438 (Tazemetostat, TAZVERIKTM) has been approved for the treatment of follicular lymphoma and epithelioid sarcoma, and EPZ5676 (Pinometostat), an inhibitor targeting DOT1L, as well as PRMT5 inhibitors (e.g. JNJ-6461978 and GSK-3326595) have entered clinical trials1. This evidence concerns the gene PRMT5 and epithelioid sarcoma.